Ascendis director plans $62K Rule 144 share sale

Ascendis Pharma A/S (ASND) is the issuer for a planned resale of 236 ordinary shares under Rule 144 for the account of director Lars Holtugcompensation-related shares to cover income tax obligations, with Citigroup Global Markets as the broker.

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) is the issuer for a planned resale of 236 ordinary shares under Rule 144 for the account of director Lars Holtugcompensation-related shares to cover income tax obligations, with Citigroup Global Markets as the broker.

Key Figures

Ordinary shares to be sold: 236 shares Indicative market price per share: 264.1296 Approximate aggregate value of shares: $62,334.59 +1 more

4 metrics

Ordinary shares to be sold 236 shares Proposed sale of Ascendis Pharma A/S ordinary shares under Rule 144

Indicative market price per share 264.1296 Basis for Section 3(d) valuation in the remarks

Approximate aggregate value of shares $62,334.59 Value shown for 236 ordinary shares of Ascendis Pharma A/S

Date of notice September 2, 2026 Date the Rule 144 notice was filed

Key Terms

Rule 144, ordinary shares, indicative market price, compensation

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

ordinary shares financial

"ORDINARY SHARES | CITIGROUP GLOBAL MARKETS"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

indicative market price financial

"SECTION 3 D IS BASED ON INDICATIVE MARKET PRICE 264.1296."

compensation financial

"SALE OF SHARES TO COVER INCOME TAX ... COMPENSATION"

FAQ

What is being sold under this Rule 144 filing for ASND?

The notice covers the proposed sale of 236 ordinary shares of Ascendis Pharma A/S (ASND) held in a share plan account for the account of director Lars Holtug.

Who is the person selling Ascendis Pharma A/S (ASND) shares in this Form 144?

The Form 144 relates to sales for the account of Lars Holtug, identified as a director of Ascendis Pharma A/S.

What is the purpose of the ASND share sale disclosed in this Form 144?

According to the remarks, the sale of the 236 ordinary shares is to cover income tax arising from compensation-related shares in a share plan account.

What price information is given for the ASND shares in the Rule 144 notice?

The remarks state that the Section 3(d) information is based on an indicative market price of 264.1296 per share, which is used for valuation in the notice.

Which broker is handling the proposed ASND Rule 144 sale?

The ordinary shares are listed as being sold through Citigroup Global Markets, located at 390 Greenwich St, New York, NY 10013.

When was the Rule 144 notice for ASND filed?

The date of notice on the Form 144 is September 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 12:53 PM Accepted by SEC EDGAR 09/02/2026 - 12:52 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001965626
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ascendis Pharma A/S
SEC File Number	001-36815
Address of Issuer	TUBORG BOULEVARD 12 HELLERUP DENMARK DK2900
Phone	45 70 22 22 44
Name of Person for Whose Account the Securities are To Be Sold	HOLTUG LARS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	236	62334.59	61977408	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/02/2026	SHARE PLAN ACCOUNT	ASCENDIS PHARMA A/S			236	03/02/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SECTION 3 D IS BASED ON INDICATIVE MARKET PRICE 264.1296. UNDER SECURITIES TO BE SOLD DATE ACQUIRED ARE VARIOUS. SALE OF SHARES TO COVER INCOME TAX
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)